Serum calcium, albumin and tumor stage in cutaneous malignant melanoma

Mridul Datta; Paul Savage; James Lovato; Gary G. Schwartz

doi:10.2217/fon-2016-0046

Serum calcium, albumin and tumor stage in cutaneous malignant melanoma

Mridul Datta, Paul Savage, James Lovato, Gary G. Schwartz

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Aim: Assess the relationship of serum calcium and serum albumin to tumor stage and other clinical characteristics in patients with cutaneous malignant melanoma (MM). Patients & methods: A cross-sectional study to evaluate serum calcium as a marker of disease progression (n = 644) in MM. Results: Serum albumin was significantly lower among men (p < 0.01) and among patients with stage 4 disease (p < 0.05). In a multivariable regression model adjusted for age, gender and site, albumin-corrected calcium was positively associated with disease stage (odds ratio: 1.46; 95% CI: 1.02-2.07; p = 0.04). The odds of higher stage increased 60% for each 1.0 mg/dl increase in albumin-corrected calcium. Conclusion: Higher albumin-corrected serum calcium may be a marker of disease progression in MM.

Original language	English (US)
Pages (from-to)	2205-2214
Number of pages	10
Journal	Future Oncology
Volume	12
Issue number	19
DOIs	https://doi.org/10.2217/fon-2016-0046
State	Published - Oct 2016
Externally published	Yes

Keywords

Albumin
Albumin-corrected calcium
Malignant melanoma
Serum calcium

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2016-0046

Cite this

@article{88109b3574174d4993064e3f9b4b80b6,

title = "Serum calcium, albumin and tumor stage in cutaneous malignant melanoma",

abstract = "Aim: Assess the relationship of serum calcium and serum albumin to tumor stage and other clinical characteristics in patients with cutaneous malignant melanoma (MM). Patients & methods: A cross-sectional study to evaluate serum calcium as a marker of disease progression (n = 644) in MM. Results: Serum albumin was significantly lower among men (p < 0.01) and among patients with stage 4 disease (p < 0.05). In a multivariable regression model adjusted for age, gender and site, albumin-corrected calcium was positively associated with disease stage (odds ratio: 1.46; 95% CI: 1.02-2.07; p = 0.04). The odds of higher stage increased 60% for each 1.0 mg/dl increase in albumin-corrected calcium. Conclusion: Higher albumin-corrected serum calcium may be a marker of disease progression in MM.",

keywords = "Albumin, Albumin-corrected calcium, Malignant melanoma, Serum calcium",

author = "Mridul Datta and Paul Savage and James Lovato and Schwartz, {Gary G.}",

note = "Funding Information: M Datta was supported by the Comprehensive Cancer Center of Wake Forest University Cancer Control Traineeship - NCI/NIH Grant# R25CA122061. Biostatistical services were supported by the Comprehensive Cancer Center of Wake Forest University NCI CCSG P30CA012197 grant. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed Publisher Copyright: {\textcopyright} 2016 Future Medicine Ltd.",

year = "2016",

month = oct,

doi = "10.2217/fon-2016-0046",

language = "English (US)",

volume = "12",

pages = "2205--2214",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "19",

}

TY - JOUR

T1 - Serum calcium, albumin and tumor stage in cutaneous malignant melanoma

AU - Datta, Mridul

AU - Savage, Paul

AU - Lovato, James

AU - Schwartz, Gary G.

N1 - Funding Information: M Datta was supported by the Comprehensive Cancer Center of Wake Forest University Cancer Control Traineeship - NCI/NIH Grant# R25CA122061. Biostatistical services were supported by the Comprehensive Cancer Center of Wake Forest University NCI CCSG P30CA012197 grant. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed Publisher Copyright: © 2016 Future Medicine Ltd.

PY - 2016/10

Y1 - 2016/10

N2 - Aim: Assess the relationship of serum calcium and serum albumin to tumor stage and other clinical characteristics in patients with cutaneous malignant melanoma (MM). Patients & methods: A cross-sectional study to evaluate serum calcium as a marker of disease progression (n = 644) in MM. Results: Serum albumin was significantly lower among men (p < 0.01) and among patients with stage 4 disease (p < 0.05). In a multivariable regression model adjusted for age, gender and site, albumin-corrected calcium was positively associated with disease stage (odds ratio: 1.46; 95% CI: 1.02-2.07; p = 0.04). The odds of higher stage increased 60% for each 1.0 mg/dl increase in albumin-corrected calcium. Conclusion: Higher albumin-corrected serum calcium may be a marker of disease progression in MM.

AB - Aim: Assess the relationship of serum calcium and serum albumin to tumor stage and other clinical characteristics in patients with cutaneous malignant melanoma (MM). Patients & methods: A cross-sectional study to evaluate serum calcium as a marker of disease progression (n = 644) in MM. Results: Serum albumin was significantly lower among men (p < 0.01) and among patients with stage 4 disease (p < 0.05). In a multivariable regression model adjusted for age, gender and site, albumin-corrected calcium was positively associated with disease stage (odds ratio: 1.46; 95% CI: 1.02-2.07; p = 0.04). The odds of higher stage increased 60% for each 1.0 mg/dl increase in albumin-corrected calcium. Conclusion: Higher albumin-corrected serum calcium may be a marker of disease progression in MM.

KW - Albumin

KW - Albumin-corrected calcium

KW - Malignant melanoma

KW - Serum calcium

UR - http://www.scopus.com/inward/record.url?scp=84988649543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988649543&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0046

DO - 10.2217/fon-2016-0046

M3 - Review article

C2 - 27306120

AN - SCOPUS:84988649543

SN - 1479-6694

VL - 12

SP - 2205

EP - 2214

JO - Future Oncology

JF - Future Oncology

IS - 19

ER -

Serum calcium, albumin and tumor stage in cutaneous malignant melanoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this